Time for hepatocellular carcinoma immunotherapy: insights for successful clinical applications in this challenging tumor

Abstract

The multiplicity and phenotype of intratumoral immune infiltrate have been shown to influence the clinical outcome of hepatocellular carcinoma (HCC), thus providing a strong rationale to therapeutic interventions aimed at restoring the dysfunctional immune response against the tumor. Improving the knowledge of the complex interactions between transformed hepatocytes, nonparenchymal resident cells, and infiltrating immune cells (characterizing the HCC microenvironment) will be instrumental to increase the success rate of existing immunotherapeutic strategies and to identify new potential targets for intervention or biomarkers to optimize the selection of candidate patients.

Keywords

Hepatocellular carcinoma / immune checkpoint inhibitors / T lymphocytes / cytotoxic T lymphocytes / natural killer cells / macrophages / cytokines

References

[1] Thomson AW.Antigen-presenting cell function in the tolerogenic liver environment.Nat Rev Immunol2010;10:753-66

[2] Moris D,Qian S.Mechanisms of liver-induced tolerance.Curr Opin Organ Transplant2016;22:71-8

[3] Flecken T,Hild S,Drognitz O,Schemmer P,Eiermann T,Blum HE,Thimme R.Immunodominance and functional alterations of tumor-associated antigen-specific CD8+ T-cell responses in hepatocellular carcinoma.Hepatology2014;59:1415-26 PMCID:PMC4139003

[4] Unitt E,Gelson W,Davies S,Morris LS,Alexander GJ.Tumour lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver transplantation.J Hepatol2006;45:246-53

[5] Wada Y,Kutami R,Kojiro M.Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration.Hepatology1998;27:407-14

[6] Fu J,Zhou L,Xing S,Shi J,Liu Z,Jin L,Lau GK,Wang FS.Impairment of CD4+ cytotoxic T cells predicts poor survival and high recurrence rates in patients with hepatocellular carcinoma.Hepatology2013;58:139-49

[7] Cai L,Zhou L,Fu J,Shi M,Yang Y,Tien P.Functional impairment in circulating and intrahepatic NK cells and relative mechanism in hepatocellular carcinoma patients.Clin Immunol2008;129:428-37

[8] Taketomi A,Shirabe K,Gion T.Natural killer cell activity in patients with hepatocellular carcinoma: a new prognostic indicator after hepatectomy.Cancer1998;83:58-63

[9] López-Vázquez A,Martínez-Borra J,Rodríguez M,Fuentes D,Gonzáez S.Protective effect of theHLA-Bw4I80 epitope and the killer cell immunoglobulin-like receptor 3DS1 gene against the development of hepatocellular carcinoma in patients with hepatitis C virus infection.J Infect Dis2005;192:162-5

[10] Cariani E,Zerbini A,Olivani A,Zanetti A,Ferrari C.HLA and killer immunoglobulin-like receptor genes as outcome predictors of hepatitis C virus-related hepatocellular carcinoma.Clin Cancer Res2013;19:5465-73

[11] Cariani E.KIR/HLA immunogenetic background influences the evolution of hepatocellular carcinoma.Oncoimmunology2013;2:e26622 PMCID:PMC3913692

[12] Cariani E,Barili V,Biasini E,Dalla Valle R,Ferrari C.Natural killer cells phenotypic characterization as an outcome predictor of HCV-linked HCC after curative treatments.Oncoimmunology2016;5:e1154249 PMCID:PMC5007972

[13] El Costa H,Aguerre-Girr M,Berrebi A,Clouet-Delannoy M,Jabrane-Ferrat N,Bensussan A,Le Bouteiller P.Critical and differential roles of NKp46- and NKp30-activating receptors expressed by uterine NK cells in early pregnancy.J Immunol2008;181:3009-17

[14] Hoechst B,Ormandy L,Zhao F,Lehner F,Greten TF.Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor.Hepatology2009;50:799-807

[15] Li H,Guo Q,Cao X.Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-β1.J Immunol2009;182:240-9

[16] Wu Y,Pan WD,Lao XM,Li XF.Monocyte/macrophage elicited natural killer cell dysfunction in hepatocellular carcinoma is mediated by CD48/2B4 interactions.Hepatology2013;57:1107-16

[17] Zhang QF,Xia Y,He QF,Ren H.Liver-infiltrating CD11b(-)CD27(-) NK subsets account for NK-cell dysfunction in patients with hepatocellular carcinoma and are associated with tumor progression.Cell Mol Immunol2017;14:819-29 PMCID:PMC5649104

[18] Prieto J,Sangro B.Immunological landscape and immunotherapy of hepatocellular carcinoma.Nat Rev Gastroenterol Hepatol2015;12:681-700

[19] Dunn GP,Ikeda H,Schreiber RD.Cancer immunoediting: from immunosurveillance to tumor escape.Nat Immunol2002;3:991-8

[20] Ringelhan M,O'Connor T,Heikenwalder M.The immunology of hepatocellular carcinoma.Nat Immunol2018;19:222-32

[21] Krummel MF.CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.J Exp Med1995;182:459-65

[22] Hato T,Greten TF,Zhu AX.Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions.Hepatology2014;60:1776-82 PMCID:PMC4211962

[23] Peggs KS,Chambers CA,Allison JP.Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies.J Exp Med2009;206:1717-25 PMCID:PMC2722174

[24] Francisco LM,Brown KE,Freeman GJ,Sharpe AH.PD-L1 regulates the development, maintenance, and function of induced regulatory T cells.J Exp Med2009;206:3015-29 PMCID:PMC2806460

[25] Nguyen LT.Clinical blockade of PD1 and LAG3—potential mechanisms of action.Nat Rev Immunol2015;15:45-56

[26] Quezada SA.Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer.Br J Cancer2013;108:1560-5 PMCID:PMC3668483

[27] Zou W.Inhibitory B7-family molecules in the tumour microenvironment.Nat Rev Immunol2008;8:467-77

[28] Noman MZ,Janji B,Karray S,Bronte V.PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation.J Exp Med2014;211:781-90 PMCID:PMC4010891

[29] Barber DL,Masopust D,Allison JP,Freeman GJ.Restoring function in exhausted CD8 T cells during chronic viral infection.Nature2006;439:682-7

[30] Shi F,Zeng Z,Liu ZW,Yang YP,Wang FS.PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients.Int J Cancer2011;128:887-96

[31] Cariani E,Zerbini A,Olivani A,Schianchi C,Silini EM,Ferrari C.Immunological and molecular correlates of disease recurrence after liver resection for hepatocellular carcinoma.PLoS One2012;7:e32493 PMCID:PMC3292571

[32] Zeng Z,Zhou L,Chen Y,Lu YY,Qu JH,Wang H,Wang FS,Yang YP.Upregulation of circulating PD-L1/PD-1 is associated with poor post-cryoablation prognosis in patients with HBV-related hepatocellular carcinoma.PLoS ONE2011;6:e23621 PMCID:PMC3164659

[33] Wang BJ.Immunostaining of PD-1/PD-ls in liver tissues of patients with hepatitis and hepatocellular carcinoma.World J Gastroenterol2011;17:3322-8 PMCID:PMC3160536

[34] Gao Q,Qiu SJ,Sho M,Zhou J,Shi YH,Xu Y.Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma.Clin Cancer Res2009;15:971-9

[35] Wada J,Kumar A,Kanwar YS.Developmental regulation, expression, and apoptotic potential of galectin-9, a β-galactoside binding lectin.J Clin Invest1997;99:2452-61 PMCID:PMC508086

[36] Zhu C,Schubart A,Imitola J,Zheng XX,Kuchroo VK.The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity.Nat Immunol2005;6:1245-52

[37] Gautron AS,de Marcken M.Enhanced suppressor function of TIM-3+FoxP3+ regulatory T cells.Eur J Immunol2014;44:2703-11 PMCID:PMC4165702

[38] Li H,Tao K,Zheng Q,Liu J,Liu C,Zou W.Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma.Hepatology2012;56:1342-51

[39] Triebel F,Baixeras E,Genevee C,Hercend T.LAG-3, a novel lymphocyte activation gene closely related to CD4.J Exp Med1990;171:1393-405

[40] Workman CJ,Dugger KJ,Vignali DA.Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3).Eur J Immunol2002;32:2255-63

[41] Wherry EJ,Kaech SM,Sarkar S,Subramaniam S,Barber DL.Molecular signature of CD8+ T cell exhaustion during chronic viral infection.Immunity2007;27:670-84

[42] Woo SR,Goldberg MV,Selby M,Bettini ML,Vogel P,Tangsombatvisit S,Netto G,Chaux A,Workman CJ,Korman AJ,Vignali DA.Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape.Cancer Res2012;72:917-27 PMCID:PMC3288154

[43] Matsuzaki J,Mhawech-Fauceglia P,Miller A,Eppolito C,Lele S,Old LJ.Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer.Proc Natl Acad Sci U S A2010;107:7875-80 PMCID:PMC2867907

[44] Pasero C.Interfering with coinhibitory molecules: BTLA/HVEM as new targets to enhance anti-tumor immunity.Immunol Lett2013;151:71-5

[45] Hokuto D,Yamato I,Obara S,Nakajima Y.Clinical impact of herpesvirus entry mediator expression in human hepatocellular carcinoma.Eur J Cancer2015;51:157-65

[46] Budhu A.The role of cytokines in hepatocellular carcinoma.J Leukoc Biol2006;80:1197-213

[47] Kalathil S,Miller A,Thanavala Y.Higher frequencies of GARP+CTLA-4+Foxp3+ T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality.Cancer Res2013;73:2435-44 PMCID:PMC3645275

[48] Hammerich L.Interleukins in chronic liver disease: lessons learned from experimental mouse models.Clin Exp Gastroenterol2014;7:297-306 PMCID:PMC4158890

[49] Erhardt A,Papadopoulos T.IL-10, regulatory T cells, and Kupffer cells mediate tolerance in concanavalin A-induced liver injury in mice.Hepatology2007;45:475-85

[50] Taga K,Tosato G.Human interleukin-10 can directly inhibit T-cell growth.Blood1993;81:2964-71

[51] Greyer M,Stock AT,Tebartz C,Mintern JD,Turner SJ,O'Keeffe M,Bedoui S.T cell help amplifies innate signals in CD8+DCs for optimal CD8+ T cell priming.Cell Rep2016;14:586-97

[52] Knolle PA,Hegenbarth S,Schmitt E,Lohse AW.IL-10 downregulates T cell activation by antigen-presenting liver sinusoidal endothelial cells through decreased antigen uptake via the mannose receptor and lowered surface expression of accessory molecules.Clin Exp Immunol1998;114:427-33 PMCID:PMC1905120

[53] Asadullah K,Volk HD.Interleukin-10 therapy-review of a new approach.Pharmacol Rev2003;55:241-69

[54] Zheng LM,Garaud F,Maxwell E,Rong H,Wang XY,King I.Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism.J Exp Med1996;184:579-84

[55] Fujii S,Shimizu T.Interleukin-10 promotes the maintenance of antitumor CD8(t) T-cell effector function in situ.Blood2001;98:2143-51

[56] Mumm JB,Zhang X,Wu L,Blaisdell S,Dai J,Sheppard C,Cutler C,LaFace D,Judo M,Langowski J,Paporello B,Sriram V,Desai B,Seghezzi W,Cannon-Carlson S,Oft M.IL-10 elicits IFNγ-dependent tumor immune surveillance.Cancer Cell2011;20:781-96

[57] Schon HT.Immunomodulatory effects of transforming growth factor beta in the liver.Hepatobiliary Surg Nutr2014;3:386-406 PMCID:PMC4273109

[58] Gorelik L,Flavell RA.Cutting edge: TGF-beta inhibits Th type 2 development through inhibition of GATA-3 expression.J Immunol2000;165:4773-7

[59] Gorelik L,Flavell RA.Mechanism of transforming growth factor beta-induced inhibition of T helper type 1 differentiation.J Exp Med2002;195:1499-505 PMCID:PMC2193549

[60] Filippi CM,Oldham JE,Togher L,Flavell RA.Transforming growth factor-beta suppresses the activation of CD8+ T-cells when naive but promotes their survival and function once antigen experienced: a two-faced impact on autoimmunity.Diabetes2008;57:2684-92 PMCID:PMC2551678

[61] McKarns SC.Distinct effects of TGF-beta 1 on CD4+ and CD8+ T cell survival, division, and IL-2 production: a role for T cell intrinsic Smad3.J Immunol2005;174:2071-83

[62] Thomas DA.TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance.Cancer Cell2005;8:369-80

[63] Khong HT.Natural selection of tumor variants in the generation of 'tumor escape' phenotypes.Nat Immunol2002;3:999-1005 PMCID:PMC1508168

[64] Bauer S,Wu J,Phillips JH,Spies T.Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA.Science1999;285:727-9

[65] Kamimura H,Tsuchiya A,Matsuda Y,Inoue M,Shirai Y,Aoyagi Y.Reduced NKG2D ligand expression in hepatocellular carcinoma correlates with early recurrence.J Hepatol2012;56:381-8

[66] Jinushi M,Tatsumi T,Sakamori R,Hayashi N.Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain A in advanced human hepatocellular carcinomas.J Hepatol2005;43:1013-20

[67] Vogelstein B,Velculescu VE,Diaz LAJr.Cancer genome landscapes.Science2013;339:1546-58 PMCID:PMC3749880

[68] Mittal D,Schreiber RD.New insights into cancer immunoediting and its three component phases—elimination, equilibrium and escape.Curr Opin Immunol2014;27:16-25 PMCID:PMC4388310

[69] Makarova-Rusher OV,Duffy AG.The yin and yang of evasion and immune activation in HCC.J Hepatol2015;62:1420-9

[70] Medina-Echeverz J,Han M.Hepatic myeloid-derived suppressor cells in cancer.Cancer Immunol Immunother2015;64:931-40

[71] Kumar V,Tcyganov E.The nature of myeloid-derived suppressor cells in the tumor microenvironment.Trends Immunol2016;37:208-20 PMCID:PMC4775398

[72] Gabrilovich DI.Myeloid-derived suppressor cells as regulators of the immune system.Nat Rev Immunol2009;9:162-74 PMCID:PMC2828349

[73] Draghiciu O,Nijman HW.Myeloid derived suppressor cells-an overview of combat strategies to increase immunotherapy efficacy.Oncoimmunology2015;4:e954829 PMCID:PMC4368153

[74] Srivastava MK,Clements VK,Ostrand-Rosenberg S.Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine.Cancer Res2010;70:68-77 PMCID:PMC2805057

[75] Lu T.Molecular pathways: tumor-infiltrating myeloid cells and reactive oxygen species in regulation of tumor microenvironment.Clin Cancer Res2012;18:4877-82 PMCID:PMC3445728

[76] Condamine T,Youn J-I J.Regulation of tumor metastasis by myeloid-derived suppressor cells.Annu Rev Med2015;66:97-110 PMCID:PMC4324727

[77] Hoechst B,Ballmaier M,Krüger C,Greten TF.A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells.Gastroenterology2008;135:234-43

[78] Gao XH,Wu J,Zhang CY,Sun YF,Qiu SJ,Fan J,Yang XR.Circulating CD14+HLA-DR-/low myeloid-derived suppressor cells predicted early recurrence of hepatocellular carcinoma after surgery.Hepatol Res2017;47:1061-71

[79] Wang D,Xie S,Feng G.The clinical and prognostic significance of CD14+HLA-DR-/low myeloid-derived suppressor cells in hepatocellular carcinoma patients receiving radiotherapy.Tumor Biol2016;37:10427-33

[80] Mizukoshi E,Arai K,Kitahara M,Iida N,Kaneko S.Myeloid derived suppressor cells correlate with patient outcomes in hepatic arterial infusion chemotherapy for hepatocellular carcinoma.Cancer Immunol Immunother2016;65:715-25

[81] Arihara F,Kitahara M,Arai K,Nakamoto Y.Increase in CD14+HLA-DR-/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis.Cancer Immunol Immunother2013;62:1421-30

[82] Kapanadze T,Ma C,Zhao F,Zender L,Felsher DW,Korangy F.Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma.J Hepatol2013;59:1007-13 PMCID:PMC3805787

[83] Eggert T,Ji J,Yevsa T,Medina-Echeverz J,Forgues M,Heikenwalder M,Zender L.Distinct functions of senescence-associated immune responses in liver tumor surveillance and tumor progression.Cancer Cell2016;30:533-47

[84] Ju C.Hepatic macrophages in homeostasis and liver diseases: from pathogenesis to novel therapeutic strategies.Cell Mol Immunol2016;13:316-27 PMCID:PMC4856798

[85] Jenne CN.Immune surveillance by the liver.Nat Immunol2013;14:996-1006

[86] Heymann F,Ludwig-Portugall I,Ergen C,Martin C,Ochando JC,Luedde T,Kurts C,Tacke F.Liver inflammation abrogates immunological tolerance induced by Kupffer cells.Hepatology2015;62:279-91

[87] Yan ML,Tian YF,Yan LN.Inhibition of allogeneic T-cell response by Kupffer cells expressing indoleamine 2,3-dioxygenase.World J Gastroenterol2010;16:636-40 PMCID:PMC2816279

[88] Knolle P,Uhrig A,Meyer zum Buschenfelde KH.Human Kupffer cells secrete IL-10 in response to lipopolysaccharide (LPS) challenge.J Hepatol1995;22:226-9

[89] Wu K,Chen L,Welling TH.Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-interactions.Cancer Res2009;69:8067-75 PMCID:PMC4397483

[90] Ostrand-Rosenberg S,Beury DW.Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression.Semin Cancer Biol2012;22:275-81 PMCID:PMC3701942

[91] Lin EY,Gnatovskiy L,Zhu L,Qian H,Pollard JW.Macrophages regulate the angiogenic switch in a mouse model of breast cancer.Cancer Res2006;66:11238-46

[92] Qian B,Im JH,Zou Y,Lang RA.A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth.PLoS One2009;4:e6562 PMCID:PMC2721818

[93] De Palma M,Galli R,Politi LS,Naldini L.Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors.Cancer Cell2005;8:211-26

[94] Murdoch C,Webster S.Expression of tie-2 by human monocytes and their responses to angiopoietin-2.J Immunol2007;178:7405-11

[95] Venneri MA,Ponzoni M,Scielzo C,Mazzieri R,Naldini L.Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer.Blood2007;109:5276-85

[96] Matsubara T,Kuroda S,Higashitani K,Miyazaki M,Hiramatsu N,Tomimaru Y,Nagano H,Takehara T.TIE2 expressing monocytes as a diagnostic marker for hepatocellular carcinoma correlates with angiogenesis.Hepatology2013;57:1416-25

[97] Josefowicz SZ,Rudensky AY.Regulatory T cells: mechanisms of differentiation and function.Annu Rev Immunol2012;30:531-64

[98] Sprinzl MF.Immune control in hepatocellular carcinoma development and progression: role of stromal cells.Semin. Liver Dis2014;34:376-88

[99] Chen KJ,Zhou L,Zhou WH,Zheng SS.Selective recruitment of regulatory T cell through CCR6-CCL20 in hepatocellular carcinoma fosters tumor progression and predicts poor prognosis.PLoS One2011;6:e24671 PMCID:PMC3173477

[100] Wiedemann GM,Vetter VK,Haubner S,Kühnemuth B,Thaler R,Ormanns S,Endres S.Cancer cell-derived IL-1α induces CCL22 and the recruitment of regulatory T cells.Oncoimmunology2016;5:e1175794 PMCID:PMC5048775

[101] Moo-Young TA,Belt BA,Hawkins WG,Goedegebuure PS.Tumor-derived TGF-beta mediates conversion of CD4+Foxp3+ regulatory T cells in a murine model of pancreas cancer.J Immunother2009;32:12-21 PMCID:PMC3862184

[102] Ormandy LA,Wedemeyer H,Greten TF.Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma.Cancer Res2005;65:2457-64

[103] Fu J,Liu Z,Zhao P,Zhang Z,Zhang H,Yao J,Wang H,Fu YX.Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients.Gastroenterology2007;132:2328-39

[104] Gao Q,Fan J,Wang XY,Xu Y,Tang ZY.Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection.J Clin Oncol2007;25:2586-93

[105] Zhou J,Pan W,Li L.Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients.Int J Cancer2009;125:1640-8

[106] Neaud V,Guirouilh J,Balabaud C,Rosenbaum J.Human hepatic myofibroblasts increase invasiveness of hepatocellular carcinoma cells: evidence for a role of hepatocyte growth factor.Hepatology1997;26:1458-66

[107] Höchst B,Sauerborn P,Gevensleben H,Heukamp LC,Ballmaier M,Müller I,Kurts C,Diehl L.Activated human hepatic stellate cells induce myeloid derived suppressor cells from peripheral blood monocytes in a CD44-dependent fashion.J Hepatol2013;59:528-35

[108] Resheq YJ,Ward ST,Garg A,Blahova M,Jitschin R,Mackensen A,Adams DH.Contact-dependent depletion of hydrogen peroxide by catalase is a novel mechanism of myeloid-derived suppressor cell induction operating in human hepatic stellate cells.J Immunol2015;194:2578-86

[109] Dunham RM,Velazquez VM,Denning TL,Grakoui A.Hepatic stellate cells preferentially induce Foxp3+ regulatory T cells by production of retinoic acid.J Immunol2013;190:2009-16 PMCID:PMC3575565

[110] Yu MC,Liang X,Gandhi CR,Lu L.Inhibition of T-cell responses by hepatic stellate cells via B7-H1-mediated T-cell apoptosis in mice.Hepatology2004;40:1312-21

[111] Ji J,Budhu A,Takai A,Ye Q,Kim JH,Wang XW.Hepatic stellate cell and monocyte interaction contributes to poor prognosis in hepatocellular carcinoma.Hepatology2015;62:481-95 PMCID:PMC4515211

[112] Bricard G,Devevre E,Barbey C,Im JS,Martinet O,Cerottini JC,Porcelli SA,Speiser DE.Enrichment of human CD4+ V(alpha)24/Vbeta11 invariant NKT-cells in intrahepatic malignant tumors.J Immunol2009;182:5140-51

[113] Quail DF.Microenvironmental regulation of tumor progression and metastasis.Nat Med2013;19:1423-37 PMCID:PMC3954707

[114] Xiao X,Chen MM,Wei Y,Chen DP,Zhao Q,Liu CL,Kuang DM.PD-1hi identifies a novel regulatory B-cell population in human hepatoma that promotes disease progression.Cancer Discov2016;6:546-59

[115] Carambia A,Schwinge D,Laschtowitz A,Wraith DC,Schramm C,Heeren J.TGF-β-dependent induction of CD4+CD25+Foxp3+ Tregs by liver sinusoidal endothelial cells.J Hepatol2014;61:594-9

[116] Han Y,Yang Y,Gu Y,Lin C,Yu Y,Zhou W.Human CD14+ CTLA-4+ regulatory dendritic cells suppress T-cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma.Hepatology2014;59:567-79

[117] Zhao F,Gamrekelashvili J,Voigtländer T,Ylaya K,Hewitt SM,Korangy F.Human CCR4+CCR6+Th17 cells suppress autologous CD8+ T cell responses.J Immunol2012;188:6055-62 PMCID:PMC3370143

[118] Brandau S,Lang S.Protumor and antitumor functions of neutrophil granulocytes.Semin Immunopathol2013;35:163-76

[119] Zhou SL,Hu ZQ,Wang Z,Fan J,Dai Z.Tumor-associated neutrophils recruit macrophages and T-regulatory cells to promote progression of hepatocellular carcinoma and resistance to sorafenib.Gastroenterology2016;150:1646-58

[120] Li T,Hua X,Liu W,Tai Y,Chen G.Hepatocellular carcinoma-associated fibroblasts trigger NK cell dysfunction via PGE2 and IDO.Cancer Lett2012;318:154-61

[121] Deng Y,Fu B,Chen G,Yang Y.Hepatic carcinoma-associated fibroblasts enhance immune suppression by facilitating the generation of myeloid-derived suppressor cells.Oncogene2016;36:1090-101

[122] Takayama T,Makuuchi M,Kosuge T,Shimada K,Hirohashi S,Kakizoe T.Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial.Lancet2000;356:802-7

[123] Ma Y,Tang L,Wang J.Cytokine-induced killer (CIK) cell therapy for patients with hepatocellular carcinoma: efficacy and safety.Exp Hematol Oncol2012;1:11 PMCID:PMC3514101

[124] Xu L,Kim Y,Zhang YJ,Li YQ,Pawlik TM,Li SP.A randomized controlled trial on patients with or without adjuvant autologous cytokine-induced killer cells after curative resection for hepatocellular carcinoma.Oncoimmunology2015;5:e108367

[125] Lee JH,Lim YS,Song TJ,Gwak GY,Kim YJ,Yoon JH.Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma.Gastroenterology2015;148:1383-91

[126] Lee JH,Lee M,Song JS,Lee H,Lee KW,Bae YS.A phase I/IIa study of adjuvant immunotherapy with tumour antigen-pulsed dendritic cells in patients with hepatocellular carcinoma.Br J Cancer2015;113:1666-76 PMCID:PMC4702003

[127] Shimizu Y,Yoshikawa T,Sawada Y,Nakatsura T.Cancer immunotherapy-targeted glypican-3 or neoantigens.Cancer Sci2018;109:531-41 PMCID:PMC5834776

[128] Palmer DH,Mirza N,Ahmed F,Steven NM,Young LS.A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma.Hepatology2009;49:124-32

[129] Tsuchiya N,Fujinami N,Mizuno S,Endo I.Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma.Oncoimmunology2017;6:e1346764 PMCID:PMC5665076

[130] Sawada Y,Ofuji K,Tsuchiya N,Nobuoka D,Takahashi S,Konishi M,Ikeda M,Yamazaki N,Takayama T,Uesaka K,Endo I.Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients.Oncoimmunology2016;5:e1129483 PMCID:PMC4910752

[131] Heo J,Ruo L,Rose S,Cho M,Chung HC,Burke J,Hickman T,Lee YS,Daneshmand M,Longpre L,Rooney C,Rhee BG,Hwang TH.Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer.Nat Med2013;19:329-36 PMCID:PMC4268543

[132] Hoseini SS.Immunotherapy of hepatocellular carcinoma using chimeric antigen receptors and bispecific antibodies.Cancer Lett2017;399:44-52

[133] Qasim W,Gehring AJ,Schurich A,Zhan H,Gilmour K,Moriconi F,Mazzoni A,Morris E,Maini MK,Stauss H.Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient.J Hepatol2015;62:486-91

[134] Sangro B,de la Mata M,Garralda E,Riezu-Boj JI,Alfaro C,Lasarte JJ,Melero I.A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C.J Hepatol2013;59:81-8

[135] El-Khoueiry AB,Yau T,Kudo M,Kim TY,Trojan J,Meyer T,Yeo W,Anderson J,Lang L,Tang H,Melero I.Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.Lancet2017;389:2492-502

[136] Brown ZJ,Steinberg SM,Greten TF.Safety in treatment of hepatocellular carcinoma with immune checkpoint inhibitors as compared to melanoma and non-small cell lung cancer.J Immunother Cancer2017;5:93 PMCID:PMC5697069

[137] Duffy AG,Makorova-Rusher O,Wedemeyer H,Davis JL,Heller T,Uppala A,Kleiner DE,Venzon D,Venkatesan AM,Abi-Jaoudeh N,Wood BJ.Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma.J Hepatol2017;66:545-51 PMCID:PMC5316490

[138] Versteven M,Marcq E,Van Tendeloo VFI,Lion E.Dendritic cells and programmed death-1 blockade: a joint venture to combat cancer.Front Immunol2018;9:394 PMCID:PMC5863527

[139] Herbst RS,Kowanetz M,Hamid O,Sosman JA,Powderly JD,Kohrt HE,Lawrence DP,Leabman M,Mokatrin A,Hegde PS,Chen DS.Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.Nature2014;515:563-67 PMCID:PMC4836193

[140] Gibney GB,Atkins MB.Predictive biomarkers for checkpoint inhibitor-based immunotherapy.Lancet Oncol2016;16:e542-51

[141] Balar AV.PD-1 and PD-L1 antibodies in cancer: current status and future directions.Cancer Immunol Immunother2017;66:551-64

[142] Dijkstra KK,Schumacher TN.Genomics- and transcriptomics-based patient selection for cancer treatment with immune checkpoint inhibitors: a review.JAMA Oncol2016;2:1490-5

[143] Le DT,Smith KN,Bartlett BR,Lu S,Wilt C,Wong F,Rucki AA,Donehower R,Fisher GA,Lee JJ,Duffy AG,Eyring AD,Joe A,Holdhoff M,Cope L,Zhou S,Armstrong DK,Fader AN,Housseau F,Xiao N,Papadopoulos N,Eshleman JR,Anders RA.Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.Science2017;357:409-13 PMCID:PMC5576142

[144] Breuhahn K,Haddad R,Stippel D,Nussbaum T,Haab BB.Molecular profiling of human hepatocellular carcinoma defines mutually exclusive interferon regulation and insulin-like growth factor II overexpression.Cancer Res2004;64:6058-64

[145] Budhu A,Ye QH,He P,Kammula U,Qin L,Wang XW.Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment.Cancer Cell2006;10:99-111

[146] Chiang DY,Hoshida Y,Newell P,LeBlanc AC,Thung SN,Tovar V,Ramos AH,Roayaie S,Waxman S,Mazzaferro V,Najfeld V,Sellers WR,Llovet JM.Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.Cancer Res2008;68:6779-88 PMCID:PMC2587454

[147] Sakai Y,Fujinaga H,Mizukoshi E,Kaneko S.Common transcriptional signature of tumor-infiltrating mononuclear inflammatory cells and peripheral blood mononuclear cells in hepatocellular carcinoma patients.Cancer Res2008;68:10267-79

[148] Hoshida Y,Kobayashi M,Chiang DY,Gupta S,Wrobel MJ,Reich M,Glickman JN,Hashimoto M,Daidone MG,Schwartz M,Salvesen HB,Mazzaferro V,Friedman SL,Llovet JM.Gene expression in fixed tissues and outcome in hepatocellular carcinoma.N Engl J Med2008;359:1995-2004 PMCID:PMC2963075

[149] Sia D,Martinez-Quetglas I,Villacorta-Martin C,Putra J,Bassaganyas L,Losic B,Thung SN,Esteller M,Schwartz M,Llovet JM.Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features.Gastroenterology2017;153:812-26

[150] Carone C,Dalla Valle R,Silini EM,Missale G.Immune gene expression profile in hepatocellular carcinoma and surrounding tissue predicts time to tumor recurrence.Liver Cancer2018;

[151] Ayers M,Nebozhyn M,Loboda A,Albright A,Kang SP,Piha-Paul SA,Seiwert TY,McClanahan TK.IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade.J Clin Invest2017;127:2930-40 PMCID:PMC5531419

[152] Spranger S,Gajewski TF.Melanoma-intrinsic b-catenin signalling prevents anti-tumour immunity.Nature2015;523:231-5